Health X Platform working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

38.50×	38.50×	40.56×	43.91×	55.94×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.44×	2.44×	8.64×	10.31×	12.31×
1.38×	1.38×	1.05×	1.17×	0.84×
51.01×	51.01×	0.13×	6.52×	1.05×
1.42×	1.42×	0.31×	7.05×	2.38×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

HEALTHX₹279.20

Health X Platform Limited

· Pharma & Health

₹ CrorePeersSURAKSHA KRSNAA NEPHROPLUS 3BBLACKBIOMcap ₹888 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Inventory Days (DIO)	55.94	43.91	40.56	38.50	38.50
Receivable Days (DSO)	12.31	10.31	8.64	2.44	2.44
Asset Turnover	0.84	1.17	1.05	1.38	1.38
Cash Conversion (CFO/Net Income)	1.05	6.52	0.13	51.01	51.01
CFO/EBITDA	2.38	7.05	0.31	1.42	1.42

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.